Skip to content

A real-world study of carilli Zumab in patients with advanced lung cancer

A real-world study of carilli Zumab in patients with advanced lung cancer

Status
Recruiting
Phases
Phase 4
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2000034595
Enrollment
Unknown
Registered
2020-07-11
Start date
2020-07-12
Completion date
Unknown
Last updated
2020-07-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung Cancer

Interventions

Case series:non-interfering

Sponsors

The First Affiliated Hospital of Anhui Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Aged >=18 years; 2. No gender restriction; 3. Patients with advanced stage IIIB-IV lung cancer confirmed by histopathology or cytology; 4. Subjects voluntarily participate in this study, sign informed consent, have good compliance and cooperate with follow-up; 5. Researchers believe that treatment can be beneficial.

Exclusion criteria

Exclusion criteria: 1. Patients with proven allergy to the test drug and / or its excipients; 2. The subject has an immunodeficiency disease or a history of organ transplantation; 3. Pregnant or lactating women; 4. Patients judged by the researcher as not suitable for inclusion in this study.

Design outcomes

Primary

MeasureTime frame
progression free survival;

Secondary

MeasureTime frame
Overall Suivival;objective remission rate;Disease control rate;Duration of response;Adverse event;

Countries

China

Contacts

Public ContactGu Kangsheng

The First Affiliated Hospital of Anhui Medical University

13805692145@163.com+86 13805692145

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 15, 2026